Elizabeth A. Bonner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Elizabeth A. Bonner has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Derek L. Stirewalt
Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington
26 shared publications - Erica Arriaga-Gomez
Translational Science and Therapeutics Division, Fred Hutchison Cancer Center, Seattle, WA, USA
26 shared publications - Evan Nguyen
Translational Science and Therapeutics Division, Fred Hutchison Cancer Center, Seattle, WA, USA
26 shared publications - Sayantani Sinha
Translational Science and Therapeutics Division, Fred Hutchison Cancer Center, Seattle, WA, USA
26 shared publications - Stanley Cw Lee
Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA
26 shared publications - Alexander J. McKeeken
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
25 shared publications
Latest Publications
- Open Access
CDK8 is a critical effector of cell fate dysregulation in SF3B1 -mutant MDS
Mutations in RNA splicing factor SF3B1 are among the most common in MDS and are strongly associated with MDS with ring sideroblasts (MDS-RS). While aberrant splicing of terminal erythroid regulators has been implicated in MDS pathogenesis, the impact of SF3B1 mutations on early hematopoietic progenitor function remains unclear. Here, we identify CDK8, a key kinase of the mediator complex involved in transcriptional regulation, as a recurrent mis-spliced target in SF3B1 -mutant MDS. Mutant SF3B1 induces cryptic 3′ splice site selection in CDK8, leading to loss of CDK8 mRNA and protein. Using primary human HSPCs, our study identifies CDK8 as an important regulator of HSPC homeostasis and cell fate determination. CDK8 depletion results in expansion of HSPCs and shifts differentiation toward the erythroid and myeloid lineages, mirroring phenotypes observed in SF3B1 -mutant MDS. Lastly, functional restoration of CDK8 rescues early erythroid phenotypes in SF3B1 -mutant cells. These findings implicate CDK8 mis-splicing as a mechanistic driver of altered progenitor fate and dysplasia in SF3B1 -mutant MDS, linking aberrant splicing to transcriptional dysregulation and hematopoietic lineage commitment.
Open AccessCDK8 is a critical effector of cell fate dysregulation in SF3B1 -mutant MDS
Mutations in RNA splicing factor SF3B1 are among the most common in MDS and are strongly associated with MDS with ring sideroblasts (MDS-RS). While aberrant splicing of terminal erythroid regulators has been implicated in MDS pathogenesis, the impact of SF3B1 mutations on early hematopoietic progenitor function remains unclear. Here, we identify CDK8, a key kinase of the mediator complex involved in transcriptional regulation, as a recurrent mis-spliced target in SF3B1 -mutant MDS. Mutant SF3B1 induces cryptic 3′ splice site selection in CDK8, leading to loss of CDK8 mRNA and protein. Using primary human HSPCs, our study identifies CDK8 as an important regulator of HSPC homeostasis and cell fate determination. CDK8 depletion results in expansion of HSPCs and shifts differentiation toward the erythroid and myeloid lineages, mirroring phenotypes observed in SF3B1 -mutant MDS. Lastly, functional restoration of CDK8 rescues early erythroid phenotypes in SF3B1 -mutant cells. These findings implicate CDK8 mis-splicing as a mechanistic driver of altered progenitor fate and dysplasia in SF3B1 -mutant MDS, linking aberrant splicing to transcriptional dysregulation and hematopoietic lineage commitment.
- Open Access
- 15 February 2024
- Published by American Association for Cancer Research (AACR)
Table S5 from R-Loop Accumulation in Spliceosome Mutant Leukemias Confers Sensitivity to PARP1 Inhibition by Triggering Transcription–Replication Conflicts
List of inhibitors for drug screen and IC50 summary
- 15 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from R-Loop Accumulation in Spliceosome Mutant Leukemias Confers Sensitivity to PARP1 Inhibition by Triggering Transcription–Replication Conflicts
List of inhibitors for drug screen and IC50 summary
- Open Access
- 15 February 2024
- Published by American Association for Cancer Research (AACR)
Table S9 from R-Loop Accumulation in Spliceosome Mutant Leukemias Confers Sensitivity to PARP1 Inhibition by Triggering Transcription–Replication Conflicts
Differential gene expression of K562 U2AF1-WT and U2AF1-S34F cells
- 15 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S9 from R-Loop Accumulation in Spliceosome Mutant Leukemias Confers Sensitivity to PARP1 Inhibition by Triggering Transcription–Replication Conflicts
Differential gene expression of K562 U2AF1-WT and U2AF1-S34F cells
- Open Access
- 15 February 2024
- Published by American Association for Cancer Research (AACR)
Table S7 from R-Loop Accumulation in Spliceosome Mutant Leukemias Confers Sensitivity to PARP1 Inhibition by Triggering Transcription–Replication Conflicts
Differential gene expression of K562 SRSF2-WT and SRSF2-P95H cells
- 15 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S7 from R-Loop Accumulation in Spliceosome Mutant Leukemias Confers Sensitivity to PARP1 Inhibition by Triggering Transcription–Replication Conflicts
Differential gene expression of K562 SRSF2-WT and SRSF2-P95H cells
- Open Access
- 15 February 2024
- Published by American Association for Cancer Research (AACR)
Table S5 from R-Loop Accumulation in Spliceosome Mutant Leukemias Confers Sensitivity to PARP1 Inhibition by Triggering Transcription–Replication Conflicts
List of inhibitors for drug screen and IC50 summary
- 15 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from R-Loop Accumulation in Spliceosome Mutant Leukemias Confers Sensitivity to PARP1 Inhibition by Triggering Transcription–Replication Conflicts
List of inhibitors for drug screen and IC50 summary
- Open Access
- 15 February 2024
- Published by American Association for Cancer Research (AACR)
Table S8 from R-Loop Accumulation in Spliceosome Mutant Leukemias Confers Sensitivity to PARP1 Inhibition by Triggering Transcription–Replication Conflicts
Alternative splicing analysis of K562 SRSF2-WT and SRSF2-P95H cells
- 15 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S8 from R-Loop Accumulation in Spliceosome Mutant Leukemias Confers Sensitivity to PARP1 Inhibition by Triggering Transcription–Replication Conflicts
Alternative splicing analysis of K562 SRSF2-WT and SRSF2-P95H cells
- Open Access
- 15 February 2024
- Published by American Association for Cancer Research (AACR)
Table S10 from R-Loop Accumulation in Spliceosome Mutant Leukemias Confers Sensitivity to PARP1 Inhibition by Triggering Transcription–Replication Conflicts
Alternative splicing analysis of K562 U2AF1-WT and U2AF1-S34F cells
- 15 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S10 from R-Loop Accumulation in Spliceosome Mutant Leukemias Confers Sensitivity to PARP1 Inhibition by Triggering Transcription–Replication Conflicts
Alternative splicing analysis of K562 U2AF1-WT and U2AF1-S34F cells
- Open Access
- 15 February 2024
- Published by American Association for Cancer Research (AACR)
Table S9 from R-Loop Accumulation in Spliceosome Mutant Leukemias Confers Sensitivity to PARP1 Inhibition by Triggering Transcription–Replication Conflicts
Differential gene expression of K562 U2AF1-WT and U2AF1-S34F cells
- 15 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S9 from R-Loop Accumulation in Spliceosome Mutant Leukemias Confers Sensitivity to PARP1 Inhibition by Triggering Transcription–Replication Conflicts
Differential gene expression of K562 U2AF1-WT and U2AF1-S34F cells